Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02823340
Other study ID # XJPFMR-201506
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2016
Est. completion date December 31, 2017

Study information

Verified date March 2021
Source Xijing Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Twenty patients with PAH had 1 session of Fractionated microneedle radiofrequency treatment. Clinical improvement was evaluated using a Hyperhidrosis Disease Severity Scale (HDSS) and photographs were taken using the starch-iodine test at every visit and 4 weeks, 8 weeks, and 24 weeks after the treatment. Skin biopsies were obtained from 3 of the enrolled patients before and after treatment. The satisfaction and adverse reactions of the research participants were recorded at every follow-up visit.


Description:

Hyperhidrosis Disease Severity Scale (HDSS)Score = 1 My sweating is never noticeable and never interferes with my daily activitiesScore = 2 My sweating is tolerable but sometimes interferes with my daily activitiesScore = 3 My sweating is barely tolerable and frequently interferes with my daily activitiesScore = 4 My sweating is intolerable and always interferes with my daily activities


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 31, 2017
Est. primary completion date December 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: Meet the following conditions - Diagnosed according to having a score of 3 or 4 on a Hyperhidrosis Disease - Severity Scale (HDSS); - Patients aged 18 to 40 years (to the date of screening); - Not treatment in Axillary area before; - Understanding the whole process of the study, voluntary participation and signed the informed consent; - Patient compliance is good, can guarantee in course of observation. Exclusion Criteria:One of the following is not included in this study: - Pregnant women, ready to pregnant or lactating women; - Have a serious heart, lung, kidney and other vital organs and endocrine system lesions and the history - Need insulin control of diabetes; High blood pressure did not get good controller ; - Patients with white blood cells <4.0 × 109 / L, or a definite anemia (hemoglobin less than 100g / L), or platelets <100 × 109 / L, or other blood disease; - Patients with chronic diarrhea, or peptic ulcer nearly 1 year; - Patients suffering from malignant tumor; - Patients suffering from acute and chronic infectious diseases; - Mental disorders, history of alcohol abuse, drug or other substance abuse; - Other cases which researchers believe that can not enroll.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Fractional microneedle RF(United, Peninsula Medical, China)


Locations

Country Name City State
China Xijing Hospitial Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The improvement of Hyperhidrosis Disease Severity Scale (HDSS) up to 24 weeks
Secondary The improvement of visual analog scale(VAS) by patient 0 week, 4weeks, 8weeks, 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT03627468 - A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis Phase 3
Completed NCT03658616 - Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis. Phase 3
Completed NCT02286765 - Ulthera® System for Treating Axillary Hyperhidrosis N/A
Completed NCT04599907 - Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating N/A
Completed NCT03037788 - Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis Phase 1
Terminated NCT01722461 - A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis N/A
Completed NCT05863104 - Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis Phase 2
Not yet recruiting NCT04159610 - Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects With Primary Axillary Hyperhidrosis Phase 2
Completed NCT01799824 - Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis Phase 2
Completed NCT03785587 - A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis Phase 2
Completed NCT03054480 - Fractional Micro-Needle Radiofrequency and I Botulinum Toxin A for Primary Axillary Hyperhidrosis N/A